Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Immunogen Inc (IMGN) Com Stock USD 0.01

Sell:$1.87 Buy:$1.88 Change: $0.09 (4.59%)
NASDAQ:0.16%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.87
Buy:$1.88
Change: $0.09 (4.59%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.87
Buy:$1.88
Change: $0.09 (4.59%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Contact details

Address:
830 WINTER ST
WALTHAM
02451-1477
United States
Telephone:
+1 (781) 8950600
Website:
www.immunogen.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMGN
ISIN:
US45253H1014
Market cap:
$293.08 million
Shares in issue:
149.53 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Stephen McCluski
    Independent Chairman of the Board
  • Mark Enyedy
    President, Chief Executive Officer, Director
  • Richard Gregory
    Executive Vice President - Research, Chief Scientific Officer
  • Craig Barrows
    Executive Vice President, General Counsel, Secretary
  • Blaine Mckee
    Executive Vice President and Chief Business Officer
  • Anna Berkenblit
    Senior Vice President and Chief Medical Officer
  • Theresa Wingrove
    Senior Vice President - Regulatory Affairs and Quality
  • Thomas Ryll
    Vice President, Technical Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.